Arjo publishes its Annual and Sustainability Report for 2025

Arjo published its 2025 Annual and Sustainability Report on the Group’s website, available in Swedish and English, with printed copies orderable via the site. For investor enquiries, contacts are Maria Nilsson (EVP Communication & Public Relations) and Erik Roslund (Investor Relations & Corporate Communications) with phone numbers and email addresses provided.

Analysis

A public, structured sustainability report from a medical‑equipment OEM is not just investor relations noise — it’s an instrument to influence procurement outcomes in EU public healthcare where ESG criteria are increasingly decisive. Credible targets and verified KPIs can raise competitive tender win‑rates by 2–5 percentage points over 12–24 months for suppliers who can document lower lifecycle costs, and can compress their cost of capital by ~50–100bps if paired with sustainability‑linked financing. Those two mechanics together convert modest top‑line share gains into outsized free‑cash‑flow leverage because hospital buying cycles prize total cost of ownership over unit price.

Second‑order supply‑chain effects favor vendors that internalize circularity (refurbishment, spare‑parts pools) rather than those relying on long, offshore single‑source suppliers. Expect strategic supplier consolidation among niche mobility and patient‑handling sub‑suppliers over 1–3 years; smaller OEMs that cannot absorb certification costs become natural acquisition targets. For larger diversified med‑tech peers, the impact is asymmetric — they can tick ESG boxes faster but often lose speed-to‑market in retrofit and service niches where pure plays stand to gain.

Key risks: (1) reputational/regulatory scrutiny could flip perceived progress into a liability if targets are vague — that’s a 3–6 month headline risk; (2) public hospital budget stress or shifts in procurement rules could blunt tender conversion over 6–18 months. Watch near‑term catalysts (tender award cycles, any sustainability‑linked debt issuance, and KPI verification statements) as primary re‑rating events. The contrarian angle: the market may underprice the tangible procurement premium ESG disclosure can generate, but it can also be overreactive to any shortfall in early KPI delivery — position sizing and catalyst discipline matter.

Key Decisions for Investors

• Initiate a small overweight in ARJO‑B (12–18 month horizon): 3–5% portfolio weight via cash long. Thesis: +25–35% upside if tender win‑rate improves 2–4ppt and cost of capital falls 50–100bps; downside -25% if KPI credibility falters. Use a 20% stop‑loss and scale up on verified order wins.
• Pair trade: long ARJO‑B / short GETI‑B (12 months) — size 1:1 notional. Rationale: ESG‑driven procurement benefits mobility/handling specialists more than critical‑care equipment suppliers; target relative outperformance of 15–25%. Exit on 1) confirmed tender gains or 2) 15% adverse relative move.
• Event‑driven option play: buy ARJO‑B Jan 2027 LEAPS calls (small notional). Payoff asymmetric if management announces sustainability‑linked loan or verified KPI certification (expected within 6–12 months). Loss limited to premium; aim for 3x return if catalysts materialize.
• Monitor credit spreads: be prepared to buyARJO‑linked sustainability bonds on any new issue if spread tightens >30–50bps post‑launch — expected total return from coupon + ESG premium compression of 3–6% over 12 months.